Compare Johnson & Johnson (JNJ) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kyndryl Holdings Inc — how do they compare? Johnson & Johnson trades at $260.15 (market cap $626.09B), while Kyndryl Holdings Inc trades at $12.95 (market cap $2.91B). The key difference: Johnson & Johnson is far larger — about 215.2× Kyndryl Holdings Inc's market cap, and Johnson & Johnson pays a 2.06% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| JNJ | KD | |
|---|---|---|
Market Cap | $626.09B | $2.91B |
Volume | 6,156,228 | — |
Sector | Health | Technology |
52-Week High | $267.24 | $33.14 |
52-Week Low | $172.78 | $10.59 |
Enterprise Value | $654.37B | $5.74B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Kyndryl (KD) trades at $12.87, down 5.58% on the day, with a neutral technical signal and mixed earnings history. The company reported a net income of $252 million in 2025, reversing prior losses, and maintains strong operating cash flow of $942 million. Recent news includes an acquisition to boost AI services and Q1 2027 results showing a revenue miss but an EBITDA beat.
The stock presents a cautious opportunity with a consensus price target of $13.50, offering modest upside. Risks include inconsistent earnings, high debt levels, and ongoing investigations. Analyst sentiment is predominantly hold, reflecting uncertainty amid strategic shifts toward growth areas like AI and cloud partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
